Asuragen, Inc. 1 article published in JoVE Medicine Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies Jeffrey Houghton1, Andrew G. Hadd1, Robert Zeigler1, Brian C. Haynes1, Gary J. Latham1 1Asuragen, Inc. An integrated system for targeted next-generation sequencing of oncology specimens is described. This cross-platform system is optimized for low-quality and low-quantity tumor biopsies, accommodates low DNA inputs, includes well-characterized multi-variant controls, and features a novel variant caller that is informed by quantitative pre-analytical quality control measures.